Tag: Blood Cancers
Search News
Scientists uncover a promising strategy to combat leukaemia resistance
18th May 2023
Research reveals a vulnerability in leukaemia cells that causes them to fill with toxic fatty acids
Read more
Vitamin B5 could improve red blood cell production in people with myelodysplastic syndromes
2nd March 2023
Scientists from Barts Cancer Institute at Queen Mary University of London and the Francis Crick Institute, have uncovered why patients with a rare type of blood cancer suffer from ineffective red blood cell production, and how vitamin B5 could be combined with existing drugs to improve outcomes.
Read more
Introducing Dr Özgen Deniz
21st December 2022
We are pleased to welcome Dr Özgen Deniz to Barts Cancer Institute (BCI) at Queen Mary University of London as a Lecturer and Group Leader. After receiving a Cancer Research UK Career Development Fellowship, Dr Deniz is establishing her own independent research group in BCI’s Centre for Haemato-Oncology.
Read more
BCI researcher part of Strategic Collaboration Agreement with Queen Mary, Envisagenics and Cancer Research Horizons
14th December 2022
BCI’s Dr Ana Rio-Machin is part of a new research collaboration agreement that will leverage Envisagenics’ SpliceCore® AI platform for expanded discovery and research in haematopoietic cancers.
Read more
Barts Cancer Institute at ASH 2021
17th December 2021
In December each year, the American Society of Hematology (ASH) hosts its Annual Meeting and Exposition – the premier event in malignant and non-malignant haematology. The event represents an invaluable opportunity for researchers at Barts Cancer Institute, Queen Mary University of London to highlight their blood cancer research on an international stage.
Read more
Mapping the emergence of treatment resistance in leukaemia
28th September 2021
Research led by Barts Cancer Institute, Queen Mary University of London, has identified a new role for a group of cells called adipocytes in contributing to treatment resistance in a type of leukaemia. Published in Nature Communications, the findings broaden the understanding of resistance pathways in blood cancer cells, which is critical for developing novel treatment strategies to improve outcomes for people with leukaemia.
Read more